STOCKS TELEGRAPH

Tag: VANI Stock

  • Vivani Medical (VANI) Stock Surge Following FDA Clearance

    Vivani Medical (VANI) Stock Surge Following FDA Clearance

    Following the recent regulatory approval, Vivani Medical, Inc. (NASDAQ: VANI) has experienced a notable increase in its stock value during the current market session. At the latest observation, VANI shares surged by 13.15%, reaching $1.85 on the US stock charts.

    FDA Approval And Initialization Of Clinical Trial

    The FDA has approved the Investigational New Drug Application (IND) and removed the clinical hold on NPM-119, according to a statement from Vivani Medical. Vivani is developing NPM-119, a revolutionary six-month GLP-1 implant, to treat type 2 diabetes.

    With this approval, the Phase 1 clinical research LIBERATE-1, aimed at evaluating the pharmacokinetics, safety, and tolerability of NPM-119, may now start. With a treatment candidate that shows promise in treating medication non-adherence—a issue that affects almost half of all type 2 diabetics—the approval is a significant step forward for Vivani Medical.

    LIBERATE-1: Pioneering Clinical Study

    LIBERATE-1 is Vivani Medical’s first-in-human study of NPM-119 for type 2 diabetes patients and marks the initial clinical application of its groundbreaking NanoPortal implant technology. This pivotal trial will assess how the preclinical pharmacokinetic profile of NPM-119 translates to human subjects in comparison to the marketed exenatide once-weekly active comparator, Bydureon BCise.

    The outcomes of LIBERATE-1 will also impact Vivani Medical’s leading program, NPM-115, which is being developed for chronic weight management. Preclinical studies earlier this year demonstrated that NPM-115 could achieve weight loss comparable to semaglutide injections, the active ingredient in popular products such as Ozempic and Wegovy.

    Subject to regulatory approval, the six-month dosage form of NPM-115 is poised to be a highly differentiated and appealing option in the rapidly expanding obesity market. Vivani Medical is finalizing study preparations and expects to initiate LIBERATE-1 in the latter half of the year.

    Advancing Innovative Drug Implants

    LIBERATE-1 is a randomized, 12-week investigation designed to assess the safety, tolerability, and comprehensive pharmacokinetic profile of NPM-119 in patients with type 2 diabetes. The trial will include patients who have previously undergone GLP-1 therapy, which will be discontinued before starting treatment with either NPM-119 or the active comparator.

  • Vivani (VANI) Stock Jumps More Than 400%: Clinical Trial Triumph Drives Market Surge

    Vivani (VANI) Stock Jumps More Than 400%: Clinical Trial Triumph Drives Market Surge

    Vivani Medical, Inc. (NASDAQ: VANI) has experienced a remarkable surge in its stock value, soaring by an impressive 421.77% to $5.27 per share during current session trading. This surge is attributed to the announcement of positive clinical trial results by the company. Vivani revealed encouraging preclinical data regarding the weight loss effects of its products, NPM-115 and NPM-139, both of which are implants aimed at addressing chronic weight management issues.

    NPM-115, a miniature exenatide implant designed for biannual administration, demonstrated promising results in preclinical trials for weight loss. Similarly, NPM-139, containing semaglutide, showed potential benefits for chronic weight management with the added advantage of once-yearly administration. These developments mark a strategic pivot for Vivani towards prioritizing obesity implants based on emerging data suggesting the efficacy of high-dose GLP-1 products in improving health outcomes for overweight and obese patients.

    Recognizing the significant medical need and market demand for effective obesity treatments, Vivani is redirecting its focus towards developing GLP-1 implants for obesity and chronic weight management. The company’s proprietary NanoPortal implant technology aims to enhance medication adherence and tolerability, potentially revolutionizing GLP-1 therapy. Recent data indicates that the improved adherence and persistence of Vivani’s implants compared to traditional obesity medications could significantly impact real-world patient outcomes.

    The preclinical findings also suggest that the weight loss potential of exenatide, a key component in Vivani’s implants, could rival that of other GLP-1 molecules like semaglutide, provided adequate exposure levels are achieved and maintained. Previous limitations associated with adherence and dosing in currently available exenatide products have hindered the full evaluation of their weight loss potential. NPM-115 addresses these limitations by offering continuous dosing over a six-month interval from a single administration, potentially maximizing exenatide’s weight loss effects.

    Vivani Medical’s recent stock surge is fueled by positive clinical trial results, particularly regarding its innovative obesity implants. The company’s strategic shift towards prioritizing the development of GLP-1 implants reflects a commitment to addressing significant medical needs and capitalizing on emerging data trends. With promising preclinical data supporting the efficacy of its products, Vivani is poised to advance the field of obesity treatment and improve patient outcomes in the future.